EGFR and non-small cell lung carcinoma: While our study has not directly examined CDCA3 in the emergence TKI resistance, further clinical analysis is warranted, particularly to evaluate CDCA3 expression in matched cohorts of diagnostic and relapsed EGFR mutant NSCLC.